Ophthalmology. Retina最新文献

{"title":"Re: Pandiri et al.: Telemedicine utilization for retinopathy of prematurity screening in premature infants: Systematic review and meta-analysis.","authors":"Alok Raghav, Jogender Kumar","doi":"10.1016/j.oret.2026.09.007","DOIUrl":"https://doi.org/10.1016/j.oret.2026.09.007","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Continuing Challenge of Postoperative Tilt Following the Yamane Technique.","authors":"Allen Chiang","doi":"10.1016/j.oret.2026.09.011","DOIUrl":"https://doi.org/10.1016/j.oret.2026.09.011","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Neovascular Age-Related Macular Degeneration in Routine US Clinical Practice: Impact of Delayed Treatment Initiation.","authors":"John D Pitcher, Ehsan Rahimy, Steven Sherman, Fabiana Q Silva, Hadi Moini, Nick Boucher, Stephanie B Engelhard, Andrew A Moshfeghi","doi":"10.1016/j.oret.2026.09.029","DOIUrl":"https://doi.org/10.1016/j.oret.2026.09.029","url":null,"abstract":"<p><strong>Objective: </strong>To understand management of patients with neovascular age-related macular degeneration (nAMD) in routine US clinical practice to identify gaps in patient care.</p><p><strong>Design: </strong>Retrospective analysis of electronic medical records from the Vestrum database.</p><p><strong>Participants: </strong>Treatment-naive eyes newly diagnosed with nAMD from January 1, 2014, with ≥1-years' follow-up.</p><p><strong>Methods: </strong>Cumulative incidence of eyes receiving treatment was evaluated using Kaplan-Meier, and factors predicting anti-VEGF receipt through 1 year were evaluated by logistic regression.</p><p><strong>Main outcome measures: </strong>Proportion of eyes treated over 3 years, baseline factors associated with receiving treatment within 1 year of diagnosis and with delayed (3-12 months after diagnosis) versus prompt (within 29 days of diagnosis) treatment initiation.</p><p><strong>Results: </strong>Of 90 681 eyes included in the analysis, 23% did not receive anti-VEGF treatment at diagnosis, declining to 16%, 15%, and 13% at years 1, 2, and 3, respectively. Mean baseline VA of eyes not treated and treated was 39 and 52 letters, respectively. Eyes were more likely to receive treatment (odds ratio [OR] ≥ 1.50, [95% CI]) if they had baseline VA 20/40-20/100 versus ≥ 20/40 (1.52 [1.44, 1.61]), macular edema (3.26 [3.11, 3.42]), subretinal fluid (4.97 [4.75, 5.20]), or subretinal pigment epithelium fluid (1.64 [1.56, 1.72]). Eyes were less likely to receive treatment (OR ≤ 0.50) if they had simultaneous bilateral diagnosis of nAMD vs. unilateral diagnosis (0.32 [0.31, 0.34]), or baseline VA < 20/400 versus ≥ 20/40 (0.29 [0.27, 0.30]). Mean change in VA from baseline at 1 year was +5 and -3 letters in the prompt and delayed treatment groups, respectively. Mean VA change from baseline at year 1 was -1.2, 0.6, 4.3, and 5.6 letters in eyes treated with 1-3, 4-6, 7-9, and >9 injections, respectively. In eyes that received >9 injections, those with baseline VA < 20/400 gained 27.2 letters.</p><p><strong>Conclusions: </strong>Overall, approximately one-quarter of eyes with nAMD were not treated within 29 days of diagnosis. Simultaneous bilateral nAMD diagnosis and poor baseline VA (< 20/400) were primary factors associated with not receiving anti-VEGF treatment. Greater VA gains were observed with prompt treatment and increasing number of injections.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic Retinopexy in the Fellow Eye after Contralateral Retinal Detachment: Beyond the Pooled Estimate.","authors":"Tien-En Tan, Andrew S H Tsai","doi":"10.1016/j.oret.2026.09.009","DOIUrl":"https://doi.org/10.1016/j.oret.2026.09.009","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Hong et al.: Ocular Outcomes with Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes (Ophthalmol Retina. 2026;10:625-632).","authors":"Xin Guang, Guoyu Zhang, Yuqing Wang, Hua Chai","doi":"10.1016/j.oret.2026.08.021","DOIUrl":"https://doi.org/10.1016/j.oret.2026.08.021","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Iatrogenic Iridodialysis from Misdirected Intravitreal Injection.","authors":"Samuel Farag, Andrew Farag, Ananda Kalevar","doi":"10.1016/j.oret.2026.09.017","DOIUrl":"https://doi.org/10.1016/j.oret.2026.09.017","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Brachytherapy for Choroidal Melanoma: A Preliminary Report","authors":"Soumaya Bouhout MDCM,&nbsp;Zhexuan Zhang PhD,&nbsp;John H. Suh MD,&nbsp;Arun D. Singh MD","doi":"10.1016/j.oret.2026.05.012","DOIUrl":"10.1016/j.oret.2026.05.012","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 10","pages":"Pages 1058-1060"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant Outer Retinal Tear in Retinoschisis Retinal Detachment","authors":"Utsav Shah DNB,&nbsp;Srikanta Kumar Padhy MD","doi":"10.1016/j.oret.2026.01.016","DOIUrl":"10.1016/j.oret.2026.01.016","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 10","pages":"Page e132"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146258817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence","authors":"Shahin Hallaj MD,&nbsp;Takashi Nishida MD, PhD,&nbsp;Alireza Kamalipour MD, MPH,&nbsp;Christopher A. Longhurst MD, MS,&nbsp;William R. Freeman MD,&nbsp;Sally L. Baxter MD, MSc,&nbsp;Aaron Boussina PhD","doi":"10.1016/j.oret.2026.05.016","DOIUrl":"10.1016/j.oret.2026.05.016","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the incidence of age-related macular degeneration (AMD) and neovascular AMD (nAMD) among adults with diabetes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the incidence of age-related macular degeneration (AMD) and neovascular AMD (nAMD) among adults with diabetes.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Retrospective, propensity score–matched cohort study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Retrospective, propensity score–matched cohort study.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Adults with diabetes who initiated a GLP-1RA or another noninsulin antidiabetic agent. In Epic Cosmos, 2 797 686 GLP-1RA users were matched 1:1 to 2 797 686 active comparators.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Adults with diabetes who initiated a GLP-1RA or another noninsulin antidiabetic agent. In Epic Cosmos, 2 797 686 GLP-1RA users were matched 1:1 to 2 797 686 active comparators.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We analyzed de-identified electronic health record data from Epic Cosmos and independently replicated the primary analyses in the University of California Health Data Warehouse. Individuals with prevalent AMD or nAMD and those with prior anti-VEGF treatment were excluded. One-to-one nearest-neighbor propensity score matching balanced demographics, diabetes duration, comorbidities, smoking, diabetic retinopathy, obesity, and eye-care utilization. Cumulative incidence at 1, 5, and 10 years was estimated using Kaplan–Meier methods, and adjusted associations were evaluated using multivariable Cox proportional hazards models.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;We analyzed de-identified electronic health record data from Epic Cosmos and independently replicated the primary analyses in the University of California Health Data Warehouse. Individuals with prevalent AMD or nAMD and those with prior anti-VEGF treatment were excluded. One-to-one nearest-neighbor propensity score matching balanced demographics, diabetes duration, comorbidities, smoking, diabetic retinopathy, obesity, and eye-care utilization. Cumulative incidence at 1, 5, and 10 years was estimated using Kaplan–Meier methods, and adjusted associations were evaluated using multivariable Cox proportional hazards models.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measures&lt;/h3&gt;&lt;div&gt;Incidence of any AMD and nAMD.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Incidence of any AMD and nAMD.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;In the matched Epic Cosmos cohort (total N = 5 595 372), GLP-1RA use was associated with lower cumulative incidence of any AMD at 1 year (0.187% [95% confidence interval {CI}, 0.182%–0.192%] vs. 0.294% [95% CI, 0.287%–0.301%]), 5 years (0.924% [95% CI, 0.907%–0.941%] vs. 1.278% [95% CI, 1.260%–1.296%]), and 10 years (5.561% [95% CI, 4.719%–6.549%] vs. 6.540% [95% CI, 6.017%–7.108%]); all &lt;em&gt;P&lt;/em&gt; &lt; 0.001. Unadjusted cumulative incidence of nAMD was also lower among GLP-1RA users at 1 year (0.047% vs. 0.065%), 5 years","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 10","pages":"Pages 1017-1026"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macular Buckling During Silicone Oil Removal in Pathologic Myopia with Macular Detachment or Persistent Macular Hole","authors":"Gangan Sun MS,&nbsp;Jinlian Zhan MD,&nbsp;Xinyu Xu BS,&nbsp;Xia Huang MS,&nbsp;Lin Lu MD, PhD,&nbsp;Xiujuan Zhao MD, PhD","doi":"10.1016/j.oret.2026.05.017","DOIUrl":"10.1016/j.oret.2026.05.017","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;To evaluate anatomic and functional outcomes of macular buckling (MB) performed during silicone oil removal in highly myopic eyes with persistent macular retinal detachment (RD), with or without macular hole (MH), after prior pars plana vitrectomy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;To evaluate anatomic and functional outcomes of macular buckling (MB) performed during silicone oil removal in highly myopic eyes with persistent macular retinal detachment (RD), with or without macular hole (MH), after prior pars plana vitrectomy.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This retrospective consecutive case series included 62 highly myopic eyes with silicone oil tamponade and persistent or recurrent macular detachment after vitrectomy. Eyes were classified as having MH–related RD (MH-RD, n = 51) or tractional RD (TRD, n = 11). All eyes underwent MB with silicone oil removal. The primary outcomes were retinal reattachment at 1 year and successful silicone oil removal at final follow-up, defined as an oil-free status without reinjection. Secondary outcomes included best-corrected visual acuity (BCVA) and MH status at 1 year.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;This retrospective consecutive case series included 62 highly myopic eyes with silicone oil tamponade and persistent or recurrent macular detachment after vitrectomy. Eyes were classified as having MH–related RD (MH-RD, n = 51) or tractional RD (TRD, n = 11). All eyes underwent MB with silicone oil removal. The primary outcomes were retinal reattachment at 1 year and successful silicone oil removal at final follow-up, defined as an oil-free status without reinjection. Secondary outcomes included best-corrected visual acuity (BCVA) and MH status at 1 year.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Retinal reattachment at 1 year was achieved in 59 of 62 eyes (95.2%), including 48 of 51 MH-RD eyes (94.1%) and all 11 TRD eyes (100%). Silicone oil was successfully removed in 50 eyes (80.6%). Among MH-RD eyes, 43 (84.3%) achieved type 2 MH closure, whereas 8 (15.7%) remained unclosed; no cases of type 1 closure were observed. Despite the absence of complete hole closure, durable retinal reattachment was maintained in the majority of MH-RD eyes. BCVA improved significantly in the MH-RD group (from 1.57 ± 0.50 to 1.31 ± 0.48 logarithm of the minimum angle of resolution, &lt;em&gt;P&lt;/em&gt; = 0.005), but not in the TRD group (&lt;em&gt;P&lt;/em&gt; = 0.139).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Retinal reattachment at 1 year was achieved in 59 of 62 eyes (95.2%), including 48 of 51 MH-RD eyes (94.1%) and all 11 TRD eyes (100%). Silicone oil was successfully removed in 50 eyes (80.6%). Among MH-RD eyes, 43 (84.3%) achieved type 2 MH closure, whereas 8 (15.7%) remained unclosed; no cases of type 1 closure were observed. Despite the absence of complete hole closure, durable retinal reattachment was maintained in the majority of MH-RD eyes. BCVA improved significantly in the MH-RD group (from 1.57 ± 0.50 to 1.31 ± 0.48 logarithm of the minimum angle of resolution, &lt;em&gt;P&lt;/em&gt; = 0.005),","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 10","pages":"Pages 993-999"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}